GDC-0927 (SRN-927)

GDC-0927 (SRN-927) (SRN-927) 是一种有效的、非甾体、口服生物可利用的选择性雌激素受体拮抗剂。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥6412.00

5130.00

- +
10mg

￥9625.00

7700.00

- +
25mg

￥20662.00

16530.00

- +
50mg

￥32837.00

26270.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

GDC-0927 (SRN-927) is a novel, potent, non-steroidal, orally bioavailable, selective estrogen receptor antagonist.

GDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor regression in estrogen receptor (ER)+breast cancer (BC) patient-derived xenograft models[1].

[1]. MN Dickler, et al. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC). AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD5-10.